Finally, we demonstrate the synergistic potential of concurrent pharmacological targeting on UCK2 and EGFR in HCC treatment in both xenograft and patient-derived xenograft (PDX) models. The gene discussed is EGFR; the disease is hepatocellular carcinoma.